Compare ADMA Biologics Inc (ADMA) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Emerson Electric Co. — how do they compare? ADMA Biologics Inc trades at $9.89 (market cap $2.22B), while Emerson Electric Co. trades at $164.59 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 41.3× ADMA Biologics Inc's market cap, and Emerson Electric Co. pays a 1.35% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EMR | |
|---|---|---|
Market Cap | $2.22B | $91.69B |
Sector | Health | Industrials |
52-Week High | $20.38 | $164.38 |
52-Week Low | $7.60 | $123.30 |
Enterprise Value | $2.29B | $102.77B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Emerson Electric (EMR) trades at $164.56, up 3.7% on the day, reflecting strong momentum after three consecutive quarterly earnings beats. The stock exhibits a bullish technical setup, with key resistance at $168, while fundamentals show solid revenue growth and a 13.83% net income margin. Recent news highlights Q3 2026 results exceeding expectations, driven by 7% organic growth and strategic acquisitions like Glue Inc. to bolster AI capabilities in test and measurement.
Outlook remains positive with raised 2026 guidance, though valuation multiples like a P/E of 35.97 suggest premium pricing. Risks include execution challenges in integrating acquisitions and macroeconomic pressures on industrial demand. Analyst consensus favors Buy ratings with a $171.33 price target, indicating modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
